Skip to main content

Search form

  • WEgate - European gateway for women's entrepreneurship logo

  • Menu
  • About
    • Who We Are
    • FAQs
    • Women Entrepreneurship: Facts And Figures
  • Start
    • Starting business
    • Financing and Funding
    • Legal Information
    • Market Access & Operations
      • Medicine
    • Advice & Mentoring
  • Grow
    • Growing Your Business
    • Internationalisation & Expansion Assistance
    • Business Partnerships
    • Staff & Posting Partnerships
    • Legislation & Taxation
    • Financing & Funding
    • Innovation & Research
  • Support
    • Women Entrepreneurship Websites
    • Policy Resources
    • Good Practices
    • Organisations & Associations
  • Learn
    • e-learning Resources
    • Training Programmes & Organisations
    • Mentoring & Coaching
    • Other Webcasts & Webinars
  • News & Events
    • News
    • Events Calendar
    • Blog
    • Success Stories
  • Community
    • WEgate Community
  • Newsletter
    • Newsletter Archive & Registration
  • Ask Anna
  • WEgate community
    • Login
    • Register
Close

You are here

  • Home
  • Start
  • Market Access & Operations
  • Medicine

Medicine

© iStock/ shuttertop

According to European Union (EU) law (article 1 of Directive 2001/83/EC), a medicinal product is defined as "any substance or combination of substances presented for treating or preventing disease in human beings". It is the competence of the individual EU countries to classify specific products as medicinal products.

 

If a product is classified as a medicinal product, a marketing authorisation in accordance with the pharmaceutical legislation (Regulation 726/2004 and Directive 2001/83/EC) is required for it to be placed on the EU market.

 

An application for such an authorisation documents the quality, safety and efficacy of the product.

There are several procedures for the marketing authorisation:

 

  • For the majority of conventional medicinal products, the mutual recognition and the decentralised procedure apply. The mutual recognition procedure recognises an already existing national marketing authorisation by one or more EU countries. For the decentralised procedure, an application is submitted simultaneously in several EU countries, and one of them is chosen as the ‘reference EU country’.

 

  • The centralised procedure is compulsory for certain human, and veterinary medicines. The application for the centralised procedure is made directly to the European Medicines Agency (EMA). This procedure results in a single marketing authorisation that is valid in the EU, Iceland, Liechtenstein and Norway.

 

  • For medicinal products to be marketed in one EU country only, national authorisation procedures are available.

 

Further information on the marketing authorisation procedures is available here.

 

This website is available in all official EU languages

List of Links: 
Legal framework governing medicinal products Contact the national health authorities More information on healthcare industries
Tags: 
EU Europe

With the contribution of the COSME
Programme of the European Union.

image

  • Contact us
  • Help
  • Terms & Conditions

©️ 2020 WEgate. All Rights Reserved

© 2021 WEgate - European gateway for women's entrepreneurship All rights reserved.

Follow us on social media

  • Facebook
  • Twitter
  • LinkedIn
  • Instagram
  • Youtube